CLOSE

Dialog Box

Loading...

Clinical Trials 

Clinical trials are an essential part of the development of new treatments and help to improve the diagnosis, treatment and management of people with cancer.

RCA provides information about clinical trial registries and individual clinical trials with the hope that it assists you to be informed about what clinical trials are available. However, RCA is not responsible for the content or maintenance of these sites or specific clinical trial information. We will endeavor to keep this information up to date but the reader is ultimately responsible to check the accuracy of this information.

RCA neither recommends nor endorses any clinical trials. Patients are encouraged to complete their own research into any clinical trials and possible effects and impacts to their health as a result of such trials. It is the patient’s responsibility, in consultation with their medical professional, to determine whether they wish to take part in such trials.
 
Before you consider participation in any clinical trial you should seek advice from your medical professional. 

Clinical Trial Registries

Clinical trial registries allow you to find clinical trials in Australia. A registry is defined as an organisation or website that either:

  • Lists clinical trials being conducted (or that have recently been conducted) in Australia (or internationally, including Australia)
  • Provides a mechanism for patients or others to register their interest in participating in an Australian clinical trial
  • Provides a link between potential participants and Australian clinical trials.

For Clinical Trial Registries please visit australianclinicaltrials.gov.au.

Other clinical trial registries can be found by visiting these links:

http://www.australiancancertrials.gov.au/
http://www.cancervic.org.au/trials/
http://www.cancertrialsaustralia.com/
http://www.anzctr.org.au/

Other Clinical Trials

From time to time RCA is approached by clinicians who are involved with a clinical trial to share relevant information with the patient community. Details of these trials with contact information are below.

Trial Name: The Cancer Molecular Screening and Therapeutics (MoST) Program-Screening. (ACTRN12616000908437)
Location: NHMRC Clinical Trials Centre, Level 6, Chris O'Brien Lifehouse, 119–143 Missenden Road, Camperdown NSW 2050
Description:
This study is a collaboration between the Garvan Institute of Medical Research, the Kinghorn Cancer Centre, Sydney Catalyst and the NHMRC Clinical Trials Centre, University of Sydney. The study is currently open at St Vincent’s Hospital in Darlinghurst, and will soon open at Chris O’Brien Lifehouse and St George’s Hospital in Sydney.
      The study is led by Professor David Thomas (Garvan Institute of Medical Research, The Kinghorn Cancer Centre) and Professor John Simes (NHMRC Clinical Trials Centre).
      The explosion in genomic capacity presents the opportunity to molecularly phenotype cancers in unprecedented detail. Genomic screening tools are increasingly used to guide therapeutic decisions for individual patients, yielding the notion of ‘precision’ medicine.  
      The MoST Study uses novel genomics and other molecular assays for therapeutic targets, to identify ‘actionable’ mutations for patients with advanced cancers of any kind, but with a particular focus on rare cancers. The MoST then offers multiple, parallel, signal-seeking trials of novel drugs to patents in whom an ‘actionable’ target is found.
Contact: most@ctc.usyd.edu.au

Trial Name: A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone or in Combination with 5-Fluoruracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell Carcinoma (Gorlin Syndrome)
Location:    Central Brisbane Dermatology: Level 9, Silverton Place, 101 Wickham Terrace,

                            Brisbane QLD 4000, Dr Gregory Siller, 07 3831 4382
                     Q-Pharm Pty Limited: 300C Herston Road, Herston QLD 4006,       
                            Hilary Morrison, 07 3845 3657

                     St George Dermatology and Skin Cancer Centre, Kogarah, NSW, 2217
                            Sharyn Hutchinson, 02 9587 4277, clinicaltrials@stgeorgedermatology.com.au
                     Sinclair Dermatology, Melbourne, Victoria, 3002, Rodney Sinclair 03 9654 2426
                             sinclair@epworthdermatology.com.au
Description:
This research project is testing the safety and effectiveness (efficacy) of ASN-002, (an experimental treatment) alone or in combination with 5-Fluorouracil (5-FU), an anticancer chemotherapy drug. The study will also look at the changes in your BCC(s) over time, when ASN-002 alone or in-combination with 5-FU is administered directly into the BCC(s) by intra-tumoural injection. For more information, please click here
Contact:

Trial Name: Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)
Location: Canberra Hospital, Canberra, Australian Capital Territory, Australia, 2606
                 Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia, 2310
                 Prince of Wales Hospital, Sydney, New South Wales, Australia, 2031
                 Princess Alexandra Hospital, Brisbane, Queensland, Australia, 4120
                 Ashford Cancer Centre Research, Adelaide, South Australia, Australia, 5037
                 Flinders Medical Centre, Adelaide, South Australia, Australia, 5042
                 Royal Hobart Hospital, Hobart, Tasmania, Australia, 7001
                 Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia, 3199
                 Border Medical Oncology, Wodonga, Victoria, Australia, 3690
                 Sir Charles Gairdner, Perth, Western Australia, Australia, 6009
Description:
 An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease. The study aims to determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety in comparison to imatinib alone to warrant further evaluation as a first line treatment for metastatic GIST.
Contact:
ALT GIST Coordinator, 02 9562 5000, altgist@ctc.usyd.edu.au

Trial Name: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Location:    Concord Repatriation General Hospital, Sydney, New South Wales, Australia, 2139,
                              Anthony Linton, +61 2976 77033
                    Birtinya, Queensland, Australia, 4575
                    Monash Medical Center Clayton, Victoria, Australia, 3168, Muhammad Alamgeer, +61 3992 88754
                    Cabrini Hospital Malvern, Victoria, Australia, 3144, Benjamin Brady, +61 3950 83421
                    Nedlands, Western Australia, Australia, 6009
Description:
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma

Trial Name: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Locations:     Lismore Base Hospital, New South Wales
                       Royal North Shore Hospital, New South Wales
Contact:        
Adam Boyce, 02 6629 4559, aboyce@oncnorthcoast.com.au
                       Alexander Guminski, 02 9911 7210, alexander.guminski@health.nsw.gov.au

Trial Name: A parallel group randomised, controlled, multi-centre phase II open label trial with two cohorts testing the combination of capecitabine and temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT) for the treatment of advanced pancreatic or midgut neuroendocrine tumours that are not suitable for surgery.  (ACTRN12615000909527)
Location: GI Cancer Institute @ Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050
Contact:
 controlnets@ctc.usyd.edu.au

Trial Name: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (NCT02923934)
Location: Olivia Newton John Cancer Research Centre, Heidelberg, Victoria
Contact:
Teresa.Morgan@onjcri.org.au

Trial Name: NABNEC - A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (ACTRN12616000958482)
Locations:       Royal North Shore Hospital, St Leonards, New South Wales
                         Westmead Hospital, Westmead, New South Wales
                         Calvary Mater Newcastle Hospital, Newcastle, New South Wales
                         Monash Medical Centre, Moorabbin, Victoria
                         Fiona Stanley Hospital, Murdoch, Western Australia
                         Royal Hobart Hospital, Hobart, Tasmania
Contact:
Dr Mustafa Khasraw nabnec@ctc.usyd.edu.au 
For further locations, additional information and contact details, please click here

Trial Name: InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease (ACTRN12616000061437)
Location: Flinders Medical Centre - Bedford Park, South Australia
Contact:
Dr Amitesh C Roy - interAACT@ctc.usyd.edu.au
For further locations, additional information and contact details, please click here

Trial Name: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers (NCT01587703) 
Location: Clayton, Victoria, 3168
Contact:
 arun.azad@monash.edu

Trial Name: AN OPEN-LABEL, MULTICENTRE, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK 1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Location: Border Medical Oncolgy Albury, New South Wales
Contact:
 dlong@bordermedonc.com.au
For further locations and contact details, please click here